Internal Medicine
Audio Summaries

Combined results of the TETON-1 and TETON-2 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis

The authors aimed to evaluate the efficacy of inhaled treprostinil in slowing lung function decline and improving clinical outcomes in patients with idiopathic pulmonary fibrosis (IPF) by analyzing combined results from the TETON-1 and TETON-2 trials. The study found that treprostinil significantly reduced the rate of decline in forced vital capacity and delayed clinical worsening compared to placebo, with additional benefits observed in quality of life and other secondary endpoints. These findings support the use of inhaled treprostinil as a treatment option for IPF patients.

Clinical Uses of Common Genetic Variants Associated with Common Diseases

The authors investigate why the integration of polygenic risk scores and genomic knowledge into clinical practice for common adult-onset diseases has been slow, despite advancements in genomics and the identification of numerous genetic variants associated with these conditions. They explore potential applications of these scores and pharmacogenomics in improving prevention and treatment strategies as genome sequencing becomes more accessible.

Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma

This phase 1 study investigates the safety and efficacy of anitocabtagene autoleucel (anito-cel), a BCMA-directed CAR T-cell therapy, in patients with relapsed or refractory multiple myeloma who have undergone multiple prior treatments. The results indicate a high response rate (100%) with a significant proportion achieving complete response (79%), while adverse events, particularly cytokine release syndrome and neurotoxicity, were mostly mild. The findings suggest that anito-cel may be a promising treatment option for this challenging patient population.

Five-Year Follow-Up of the Phase III ASCOT Trial of Adjuvant S-1 After Resection for Biliary Tract Cancer

The authors aimed to evaluate the long-term efficacy of adjuvant S-1 in improving overall survival (OS) in patients with resected biliary tract cancer (BTC) compared to observation alone. The 5-year follow-up results from the ASCOT trial demonstrated that S-1 significantly improved OS (64% vs. 52%) and median OS (8.2 years vs. 5.9 years), confirming its sustained survival benefit and supporting its use as a standard treatment for resected BTC.

Tenecteplase Before Thrombectomy at 4.5 to 24 Hours for Basilar Artery Occlusion: The ATTENTION LATE Randomized Clinical Trial

The study aimed to determine whether intravenous tenecteplase administered before endovascular thrombectomy (EVT) improves outcomes in patients with moderate to severe basilar artery occlusion presenting 4.5 to 24 hours after stroke onset. The findings revealed no significant difference in functional independence or safety outcomes between the tenecteplase plus EVT group and the EVT alone group, suggesting that the addition of tenecteplase does not enhance recovery in this patient population.

Etuvetidigene Autotemcel for the Treatment of Wiskott-Aldrich Syndrome

This study investigates the efficacy and safety of etuvetidigene autotemcel (etu-cel), an autologous gene therapy, for treating Wiskott-Aldrich syndrome, a rare genetic disorder. The results indicate a high overall survival rate of 96% at both 1 and 5 years post-treatment, along with a significant reduction in severe infections and bleeding events after therapy. The findings suggest that etu-cel provides a sustained clinical benefit for patients with this condition.

Biologic outcomes in severe asthma patients by smoking status: evidence from SHARP

This study investigates the efficacy of biologic treatments for severe asthma in patients with varying smoking statuses, aiming to determine whether smoking exposure affects treatment outcomes. The findings indicate that all groups, including current and ex-smokers, experienced significant improvements in asthma control and quality of life after one year of biologic therapy, challenging the prevailing reluctance to prescribe biologics to smokers. The authors advocate for further randomized controlled trials to better inform treatment guidelines for this population.

Programmed Ventricular Stimulation for Risk Stratification in Nonischemic Cardiomyopathy With Preserved or Mildly Reduced LVEF

This study investigates the efficacy of programmed ventricular stimulation (PVS) for arrhythmic risk stratification in patients with nonischemic cardiomyopathy (NICM) and preserved or mildly reduced left ventricular ejection fraction (LVEF) who do not meet current criteria for implantable cardioverter-defibrillator (ICD) implantation. The authors found that PVS was able to identify a significant proportion of patients at risk for major arrhythmic events, suggesting its potential utility in guiding ICD implantation decisions for primary prevention in this population.

Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis

The authors aimed to determine whether screening with a multicancer early-detection test, in addition to usual care, reduces the incidence of late-stage cancers (stage III or IV) compared to usual care alone. In a randomized controlled trial involving over 142,000 participants, they found no significant difference in the incidence rates of stage III or IV cancers between the two groups after three screening rounds. While there was a trend towards a lower incidence of stage IV cancers, the results were not conclusive, indicating the need for further follow-up.

Butyrylcholinesterase alleviates hepatic stellate cell activation via paracrine muscarinic signalling

The authors investigate the role of butyrylcholinesterase (BuChE) in regulating fibrosis through its effect on acetylcholine (ACh) bioavailability and downstream cholinergic signaling in hepatic stellate cells (HSCs). They find that reduced BuChE expression correlates with increased HSC activation and fibrosis, while BuChE overexpression has a protective effect. The study identifies a novel cholinergic circuit involving ChRM3 signaling that could serve as a therapeutic target for fibrosis treatment.